Positive Preliminary Results, R&D Investments, and Financial Results - Research Report on MannKind, Anacor, Sangamo, Stereotaxis, and Columbia Laboratories

NEW YORK, August 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting MannKind Corporation (NASDAQ: MNKD), Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Sangamo Biosciences, Inc. (NASDAQ: SGMO), Stereotaxis Inc. (NASDAQ: STXS), and Columbia Laboratories Inc. (NASDAQ: CBRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

MannKind Corporation Research Report

On August 14, 2013, MannKind Corporation (MannKind) announced positive preliminary results from Study 171, a Phase 3 clinical study of AFREZZA (insulin human [rDNA origin]) Inhalation Powder. AFREZZA Inhalation Powder is an investigational, rapid-acting mealtime insulin therapy administered using the Company's next generation (Gen2) Dreamboat inhaler, which is being studied in patients with type 1 diabetes. According to the Company, the study showed that AFREZZA-Gen2, when compared to insulin aspart, showed non-inferior decreases in A1c levels, significantly less hypoglycemia, considerable decreases in fasting blood glucose levels, and significant weight advantage. Further, the Company stated that changes in pulmonary function observed in the AFREZZA-Gen2 group were not different from those observed in an AFREZZA treatment group that used the Company's first-generation (MedTone) inhaler.   The Full Research Report on MannKind Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/044e_MNKD]

--

Anacor Pharmaceuticals Inc. Research Report

On August 8, 2013, Anacor Pharmaceuticals Inc. (Anacor) announced its Q2 2013 financial results. The Company's total revenues increased 33.6% YoY to $3.4 million during the quarter, primarily due to revenue for research services performed under the Gates foundation Agreement. Net loss stood at $14.1 million, or $0.36 per diluted share, in Q2 2013, compared to net loss of $14.8 million, or $0.47 per diluted share, in Q2 2012. Commenting on the results, David Perry, CEO of Anacor Pharmaceuticals, said, "We had a busy second quarter as we finalized preparations for our NDA for tavaborole, which was submitted on July 26th. This is an exciting time at Anacor as we begin to reap the benefits of the investments that we've made in drug development over the last decade and plan the commercialization of our later stage products." The Full Research Report on Anacor Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05d8_ANAC]

--

Sangamo Biosciences, Inc. Research Report

On August 14, 2013, Sangamo Biosciences, Inc. (Sangamo) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent application (US 20110301073) titled "Novel DNA-binding Proteins and Uses Thereof." The Company stated that the claims cover core architectural aspects of engineered Transcription Activator-Like Effectors, or TALEs, which enable proteins to be useful in potential therapeutic applications of genome editing or gene regulation and for the efficient use of technology in biomedical research and plant applications. Philip Gregory D. Phil, Sangamo's Vice President of Research and Chief Scientific Officer, said, "The novel architectures detailed in the issuing claims are intrinsic to the efficiency and general utility of the TALE platform and we expect them to be broadly adopted and become the industry standard." The Company's research in the field, which was initially published in a paper titled "A TALE Nuclease Architecture for Efficient Genome Editing," resulted in the filing of this patent application. The Full Research Report on Sangamo Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/52a6_SGMO]

--

Stereotaxis Inc. Research Report

On August 8, 2013, Stereotaxis Inc. (Stereotaxis) reported its Q2 2013. The Company's total revenue declined 7.4% YoY to $9.7 million during the quarter. Net loss was $3 million, or $0.37 per diluted share, in Q2 2013, compared to net income of $2.8 million, or $0.32 per diluted share, in Q2 2012. Commenting on the results, William Mills, Stereotaxis Chairman and Interim CEO, said, "In the second quarter, we achieved sequential improvement in revenue, gross margin and operating loss and secured two orders for our Niobe® ES system. One of these orders was a second system sale to a leading U.S. healthcare provider, which is one of four major integrated delivery networks in the country to invest in the Epoch™ platform. Furthermore, we saw improved utilization rates in certain strategic regions through a targeted physician plan and the implementation of territory assistants focused on driving clinical adoption. Our plan involves engaging those physicians that represent the greatest potential for volume growth and facilitating a faster pace of adoption within our installed base."The Full Research Report on Stereotaxis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b071_STXS]

--

Columbia Laboratories Inc. Research Report

On August 7, 2013, Columbia Laboratories Inc. (Columbia Laboratories) reported its Q2 2013 financial results. The Company's total product revenues increased 29% YoY to $7 million during the quarter. Net income was $2.7 million, or $0.03 per diluted share, in Q2 2013, compared to net income of $1.9 million, or $0.02 per diluted share, in Q2 2012. Commenting on the results, Frank Condella, Columbia's President and CEO, said, "We are pleased to announce another consecutive quarter of profitability and positive operating cash flows, reflecting the ongoing promotion and growth of CRINONE by Actavis and Merck Serono in their respective territories. We continue to strengthen our financial position, which we believe increases our capability to pursue strategic options to increase stockholder value." The Full Research Report on Columbia Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c87b_CBRX]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner